Oncorena AB | MedPath

FDA Approves Oncorena's IND for Novel Kidney-Specific Cancer Drug in Dialysis Patients

2 months ago

• Oncorena has received FDA approval for its IND application to begin Phase I/II trials of ONC175 (orellanine) in patients with metastatic renal cell carcinoma who require dialysis. • The Oncorella-1 study will enroll up to 75 patients with severe metastatic kidney cancer who have exhausted other treatment options, with MD Anderson Cancer Center joining Karolinska University Hospital as a trial site. • ONC175 represents a potential first-in-class treatment with a kidney-specific mechanism of action, demonstrating promising preclinical results in eradicating metastatic renal cancer cells.